- Cystic Fibrosis
- Cystic Fibrosis
- Infectious Diseases
Education & Training
- Washington State University (Pullman, WA), BS, Biochemistry, Summa Cum Laude
- University of Washington School of Medicine (Seattle, WA), MD
- University of Washington (Seattle, WA), Internal Medicine
- University of Colorado Denver, Pulmonary and Critical Care Medicine
Pulmonary inflammation, host response to Pseudomonas aeruginosa and nontuberculous mycobacteria.
1992, 2002: American Board of Internal Medicine
1997, 2007: ABIM- Critical Care
1996, 2005: ABIM- Pulmonary
Teaching or Professional Positions
2008-Present: Rebecca Runyon Bryan Chair in Cystic Fibrosis
2005-Present: Director, University of Colorado Adult Cystic Fibrosis Program
Industry Relationships & Collaborations
National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.
Affiliations with the University of Colorado Denver
2011-present: Professor, Division of Pulmonary Science and Critical Care Medicine, University of Colorado Denver
Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol. 2009 Apr;58(Pt 4):492-502.
Saavedra MT, Hughes GJ, Sanders LA, Carr M, Rodman DM, Coldren CD, Geraci MW, Sagel SD, Accurso FJ, West J, Nick JA. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2008 Nov 1;178(9):929-38.
Smoak K, Madenspacher J, Jeyaseelan S, Williams B, Dixon D, Poch KR, Nick JA, Worthen GS, Fessler MB. Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense. J Immunol. 2008 Mar 1;180(5):3305-12.
Saavedra MT, Patterson AD, West J, Randell SH, Riches DW, Malcolm KC, Cool CD, Nick JA, Dinarello CA. Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways. Am J Respir Cell Mol Biol. 2008 Jun;38(6):679-88.
Silva E, Arcaroli J, He Q, Svetkauskaite D, Coldren C, Nick JA, Poch K, Park JS, Banerjee A, Abraham E. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med. 2007 Oct;33(10):1829-39.
More Publications by This Author
Link to Faculty Publications
Link to PubMed for more papers
Cystic Fibrosis Google Knol
Bronchiectasis Google Knol